Telavancin: Difference between revisions
(Text replacement - "==References== <references/>" to "==References== <references/>") |
ClaireLewis (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Glycopeptide [[antibiotic]] active against MRSA | ||
*Dosage Forms: | *Dosage Forms: IV | ||
*Common Trade Names: | *Common Trade Names: Vibativ | ||
==Adult Dosing== | ==Adult Dosing== | ||
*10 mg/kg IV q24hr | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Unknown | ||
*Renal Dosing | *Renal Dosing | ||
** | **CrCl 30-50 mL/minute: 7.5 mg/kg IV q24hr | ||
**CrCl 10-29 mL/minute: 10 mg/kg IV q48hr | |||
**Pediatric | **Pediatric | ||
*Hepatic Dosing | *Hepatic Dosing | ||
Line 20: | Line 22: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Concomitant use of IV heparin | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Renal impairment | |||
*C. diff colitis | |||
*Prolonged QT | |||
===Common=== | ===Common=== | ||
*Nausea/vomiting, diarrhea, taste disturbance | |||
*Foamy urine | |||
*Dizziness | |||
*Rigors | |||
*Pruritus, rash | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 8hr | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Urine | ||
*Mechanism of Action: | *Mechanism of Action: Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin; inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Line 159: | Line 170: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[category:ID]] |
Latest revision as of 22:46, 23 September 2019
General
- Type: Glycopeptide antibiotic active against MRSA
- Dosage Forms: IV
- Common Trade Names: Vibativ
Adult Dosing
- 10 mg/kg IV q24hr
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown
- Renal Dosing
- CrCl 30-50 mL/minute: 7.5 mg/kg IV q24hr
- CrCl 10-29 mL/minute: 10 mg/kg IV q48hr
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Concomitant use of IV heparin
Adverse Reactions
Serious
- Renal impairment
- C. diff colitis
- Prolonged QT
Common
- Nausea/vomiting, diarrhea, taste disturbance
- Foamy urine
- Dizziness
- Rigors
- Pruritus, rash
Pharmacology
- Half-life: 8hr
- Metabolism:
- Excretion: Urine
- Mechanism of Action: Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin; inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014